86723-71-9Relevant academic research and scientific papers
Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
-
, (2008/06/13)
Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia, and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, and inducing anesthesia are disclosed by administering to an animal in need of such treatment an alkyl or azido-substituted 1,4-dihydroquinoxaline-2,3-dione or pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.
2-(1,4-Benzodioxan-2-ylalkyl)benzimidazoles useful as anti-depressants
-
, (2008/06/13)
Compounds of the formula STR1 and the pharmaceutically acceptable, non-toxic salts thereof, wherein: R is hydrogen, lower alkyl, or benzyl; X is a substitution for hydrogen at any position in the benzene ring and is selected from the group consisting of lower alkyl, lower alkoxyl, benzyl and halo; m is an integer from 0 to 4; and n is an integer from 0 to 2; are novel. These compounds have been shown to be α2 blockers, and are, therefore, anti-depressants.
